TRT denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for trt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Testosterone Replacement Therapy as Experimental — and How to Appeal

Testosterone replacement therapy (TRT) — including injectable, topical, patch, and implantable formulations — has FDA-approved indications for hypogonadism in men. An "experimental" or "investigational" denial from UnitedHealthcare is unexpected for approved TRT products used for their labeled indication; it typically arises when (a) TRT is prescribed for a use outside the labeled indication, (b) the specific formulation is newer and UHC's policy has not yet been updated to reflect current evidence, or (c) an automated review system misclassified the claim.

### Why This Denial Is Appealable

An experimental denial is one of the strongest denials to challenge when the drug has FDA approval for the condition being treated. FDA approval is itself the federal standard that a drug is not experimental for its indicated use. If your prescriber is using TRT for the labeled indication and the clinical record documents that indication, the experimental classification is likely incorrect as a matter of policy. Even for off-label uses, major clinical guidelines may support the use, and you may present that evidence in your appeal.

### Federal Appeal Framework

• Internal appeal: UHC must issue a standard decision within 30 days and an expedited decision within 72 hours for urgent situations. Always file a formal written internal appeal first.
• External review (ACA §2719): Experimental/investigational denials are explicitly eligible for independent external review. An accredited IRO applies clinical standards, not the insurer's own policy definitions.
• ERISA §503: Full-and-fair review rights apply; you are entitled to all criteria, references, and clinical guidelines used to classify the treatment as experimental.
• Timeline: File external review within approximately four months of your final internal denial. Expedited external review is available if delay would seriously jeopardize your health.

### Concrete Appeal Steps

1. Obtain the full text of UHC's experimental/investigational policy and identify the specific basis for the classification. 2. Identify the FDA-approved indication and confirm the prescriber is treating that indication. 3. Ask your prescriber to write a medical-necessity letter explicitly citing FDA-approval status, the approved indication, and the applicable clinical guideline organization (e.g., the Endocrine Society's hypogonadism guidelines) — without quoting specific numbers from those guidelines. 4. Submit internally; escalate to external review if denied, emphasizing FDA-approval status.

### Documentation to Gather

• Diagnosis confirmation: Lab work documenting the clinical basis for hypogonadism and prescriber diagnosis notes.
• Prior treatment history: Any prior therapies tried and their outcomes.
• FDA prescribing label: Print the current FDA-approved label from DailyMed and attach it — it is your primary evidence that this is not an experimental treatment for an approved indication.
• Guideline support: A letter from your prescriber referencing the relevant professional society guideline organization (without citing specific numeric thresholds).
• Clinical severity: Chart documentation of symptoms, functional impact, and clinical course.

### Criteria-Mapping Structure

Obtain UHC's published medical policy for TRT and map each criterion to chart evidence:

| UHC Policy Criterion | Supporting Evidence | |---|---| | [Copy each criterion from UHC policy] | [Lab result, chart note, prescriber letter] |

If UHC cites a specific guideline version in its denial, your prescriber should address whether current evidence — including the current FDA label — supersedes the cited reference.